Search results for: activities
Mission
About > Mission Mission To combat viral diseases through international collaborative research, surveillance, healthcare and public health solutions, professional training, public education, and policy guidance. GVN meets its mission in three ways: Research Support GVN promotes the development of pathogenesis discovery, better diagnostics, antiviral drugs, vaccines, and more. Training and Education GVN supports its…
Read MoreGlobal Virus Network (GVN) Adds Turkish Virology Consortium
Baltimore, Maryland, USA, August 7, 2023: The Global Virus Network (GVN), representing more than 70 Centers of Excellence in over 40 countries comprising foremost experts in every class of virus causing disease in humans, announced the addition of the Turkish Virology Consortium (TVC) as its newest Center of Excellence. “We are pleased to add Turkey’s leading…
Read MoreTurkey
WELCOME TO Turkey Center of Excellence Turkey For an overview of GVN Centers of Excellence, click here. Turkish Virology Consortium İzmir Tinaztepe University, Galen Research Center, Aydoğdu mahallesi, 1267/1. Sokak, No:4, 35400 Buca/İzmir Center Director: Prof. Mehmet Öztürk Management: Dr Gülhas Solmaz (Email: [email protected]) Member Researchers: Prof Hakan Abacıoğlu, Prof Neşe Atabey, Prof Fatma Sırmatel…
Read MoreGVN Announces Two New Executive Appointments
Strategic Focus On Corporate Partnerships, Content Creation and Thought Leadership Baltimore, MD, USA (May 18, 2023) – The Global Virus Network (GVN) recently appointed Andrea Ridenour as Senior Vice President of Corporate Partnerships & Development and Robert Frederick as Chief Content Officer. “Two of the GVN’s most important strategic priorities are enhancing financial development by…
Read MoreLong Covid and the Vascular Endothelium
Infection with SARS-CoV2 infection often involves the vascular endothelium, resulting in a variety of deleterious effects. Among these is endothelial dysfunction, distinct from endothelial injury, in which the vascular endothelium loses elasticity and the ability to vasodilate and vasoconstrict. It constitutes a type of non-obstructive coronary artery disease and is generally associated with impaired production…
Read MoreGVN Center and Member Spotlight – Janko Nikolich
Members > Spotlights > Janko Nikolich WELCOME TO THE GVN SPOTLIGHT ON: DR. JANKO NIKOLICH – MARCH 21, 2023 Dr. Janko Nikolich University of Arizona – Aegis Consortium Health Science Innovation Building Tucson, Arizona Professional Summary Dr. Janko Nikolich is an internationally recognized leader in immunology and gerontology. He received his M.D., MSc and Ph.D.…
Read MoreGVN Center and Member Spotlight – David Markovitz
Members > Spotlights > David Markovitz WELCOME TO THE GVN SPOTLIGHT ON: DR. DAVID MARKOVITZ – JANUARY 4, 2023 Dr. David Markovitz University of Michigan – Division of Infectious Diseases Professional Summary David Markovitz is a Professor of Internal Medicine in the Division of Infectious Diseases who also has appointments in the programs in…
Read MoreFlu Vaccines: What Does the Future Hold?
Omicron spinoffs, respiratory syncytial virus (RSV), and influenza (flu) viruses have formed a sort of unholy trinity of respiratory infections. Covid vaccines were initially highly effective against infection, hospitalization, and death, but with the multiplication of new variants, only strong protection against hospitalization and death remains. In a previous Perspective (https://gvn.org/respiratory-syncytial-virus-newly-resurgent/), we noted that the…
Read MoreLassa fever vaccine development: Where are we?
Joseph Anejo-Okopi, PhD1,2. 1Department of Microbiology, Faculty of Science, Federal University of Health Sciences Otukpo, Nigeria. 2AIDS Prevention Initiative in Nigeria, Jos University Teaching Hospital, Jos, Nigeria Email Address: [email protected], [email protected], December 5, 2022 Introduction Lassa virus (LASV) causes acute viral hemorrhagic fever (VHF) called Lassa fever (LF) that is endemic to West Africa (Nigeria,…
Read MoreVaccine and Post-Infection Immunity
Immunity against SARS-CoV-2 is acquired in two ways, infection and vaccination. How do they differ? Which is “better”? In comparisons, consideration must be given to rates of infection, transmission, hospitalization, death, and long COVID as well as innate, humoral and cell-mediated immune responses. The only correlate of protection that is currently considered robust is the…
Read More